Going from stealth to a $150 million series B in five months may seem fast, but, for Rapport Therapeutics, 10 years of toiling in the labs at Johnson & Johnson beforehand helped the neurological ...
Building rapport is a concept that is vital to sales and effective team building. But as a concept, it can be hard to understand because we tend to focus on the wrong parts of what we think are ...
Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading. The study enrolled 30 ...
Rapport Therapeutics, a young biotech company with technology from the labs of Johnson & Johnson, is now preparing to enter the public markets to finance clinical research for a lead program that ...
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small ...
According to professional speaker, consultant and founder of Cause Matters Corp Michele Payn-Knoper, building rapport with customers is critical to showing them "you're sincerely interested in a ...
BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and ...
Rapport is a key ingredient for building relationships. Building rapport involves trust, connection and creating mutual understanding. It enables you to get your message across, negotiate, leverage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback